YOUR IMMUNE SYSTEM & YOU
ABOUT TRANSFER FACTOR
4LIFE TF PRODUCTS
WORLDWIDE TESTIMONIALS
START YOUR OWN BUSINESS

About Transfer Factor | Basics of Transfer Factor | History of Transfer Factor
Who Needs Transfer Factor? | FAQ About Transfer Factor

Who Needs Transfer Factor?
Anyone—healthy or diseased, with a few exceptions—benefits from regular transfer factor supplementation. The use of transfer factor has resulted in no reports of serious adverse reactions, even when clinically administered in doses in excess of normal for prolonged periods.

Those with specific ailments also benefit. Numerous studies have shown the effectiveness of transfer factor in eliminating or alleviating symptoms of herpes, chronic fatigue syndrome, epstein barr, hepatitis, secondary infection due to AIDS, candida, cancer and many other disorders. Studies have also shown than continual use provides the greatest benefit with maximum immune activity occurring 24 to 48 hours after initial dosing.

The need for transfer factor as an adjunct to better health stems from the growing awareness that prevention is the best source of treatment. With the increasing risks of antibiotic resistance and significant health threats, such as SARS, the medical community increasingly turns to the inherent concept of vaccines—prevention.

Transfer factors are akin to vaccines. But, rather than expose the patient’s immune system to the actual disease or a deactivated version of the same, transfer factors expose the patient’s immune system to the memory of a health threat—whether foreign or native—and the knowledge of how to best respond to protect itself.

Anyone who needs a boost in immune function will need transfer factor. The need for transfer factor continues to rise significantly in conjunction with the increasing risks of antibiotic resistance and significant health threats. Moreover, there are no reported toxicity in over dosage of transfer factor.

 

Who Needs A Boost In Immune Function?
There are people who are fit, happy, strong and seem to never be ill or even catch a cold. They have “heroic” immune systems. But even heroes have bad days. Depressed immune function typically comes with age and confounding factors. Things like a poor diet, extreme diets, chronic stress, obesity and underlying disease all contribute to immune dysfunction. In this immune depressed state, disease occurs, and chronic infection and inflammation extract a huge toll in suffering and cost. The most frightening chronic disease, cancer, remains largely untreatable with conventional therapies. The hope is that advances in immunology will provide the tools to reengage the immune system to do the job it does so well.

Our understanding of transfer factors improves constantly and we stand on the threshold of amazing possibility. Transfer factors and the other immune modulators are making a difference; the world and medical science are following the lead.

Diseases and chronic infections are highly likely to attack a person with a weak immune system. Our immune system weakens by the day due to pollution, improper diet, stress, sleeping disorders as well as the pesticides and chemicals found in our daily food. Therefore, anyone who's living in an environment which weakens the immune system—needs transfer factor.

 

 
Sources:

Natural Immune Booster: Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 1998

The Super Supplement Combination for Optimal Immune Function: Enhanced Transfer Factor, William J. Hennen, Ph.D., Woodland Publishing, 2000

“Effect of Anti-Herpes Specific Transfer Factor” Byston J., Cech K, Pekarek J, Jilkova J. Biotheraphy. 1996

“Orally Adminstered HSV-Specific Transfer Factor (TF) Prevents Genital or Labial Herpes Relapses.” Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. Biotheraphy.1996.

“Efficacy of Transfer Factor in Treating Patients with Recurrent Ocular Herpes Infections.” Meduri R, Campos E, Scorolli L, De Vince C. Pizza G, Viza D. Biotherapy. 1996.

Clinical study of HSV-specific Transfer Factor on relapse HSVK. Anon. Xi’an Yike Daxue Xuebao, 1996.

“Transfer Factor Prevents Relapses in Herpes Keratitis Patients, a Pilot Study.” Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. Biotherapy. 1994.

“The Use of Transfer Factors in Chronic Fatigue Syndrome: Prospects and Problems,” Levine PH. Biotheraphy. 1996.

“Clinical, Epidemilog and Virologic Studies in Four Clusters of Chronic Fatigue Syndrome.” Lvine PH, Jacobsen S, Pockinki AG, Cheney P, Peterson D, Connelly RR, Weil R, Ablashi DV, Salahuddin SZ, Pearson GR and Hoover R. Arc Int Med. 1992.

“Inhibition of In Vitro HIV Infection by Dialyzable Leukocyte Extracts.” Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ. Biotherapy. 1996.

“Preliminary Results in HIV-1-Infected Patients Treated with Transfer Factor (TF) and Zidovudine (ZDV).” Raise E, Buerra L, Viza D, Pizza G, De Vinci C, Shiattone ML, Rocaccio L, Cicognani M, Gritti F. Biotheraphy.1996.

“Dialysable Leucocyte Extract (DLE) Reduces Lipopolysaccharide-Induced Tumour Necrosis Factor Secretion in Human Leukocytes.” Ojeda Ojeda M, Fernandez Ortega CB, Arana Rosainz MJ. Biotheraphy.1996.

“Transfer Factor in Chronic Mucocutaneous Candidiasis.” Masi M, De Vinci C, Baricordi OR. Biotherapy. 1996.

“Treatment of Chronic Mucocutaneous Candidiasis with Transfer Factor.” Kirkpatrick CH, Greenberg LE. In: Immune Regulators in Transfer Factor. Kham A, Kirkpatrick CH, Hill NO (eds). Academic Press, 1979.

“Use of Transfer Factor for the Treatment of Recurrent Non-Bacterial Female Cystitis (NBRC): A Preliminary Report.” De Vinci C, Pizza G, Cuzzocrea D, et al. Biotheraphy.1996.

“Radioprotective Effects of DLE.” Kofranek V, Barnet K, Pekarek J, Cech K. In: Research and Application of Transfer Factor and DLE. Huo B-L, Wang, R-Z, Zou Z-F (eds.) Xueyuan Press: Bejing.

“The Adjuvant Therapy of Nasopharyngeal Tumor with Transfer Factor.” Sibl O, Pekarek J, Cech K, Svejcar J. In: Research and Application of Transfer Factor and DLE. Bao-Lai H, Ru-Zhang W, Zho-Fen Z (eds.) Xueyan Press: Bejing. 1989.

“A Preliminary Report on the Use of Transfer Factor for Treating Stage D3 Hormone-Unresponsive Metastatic Prostrate Cancer. Pizza G, De Vinci C, et al. Biotherapy. 1996.

“Transfer Factor as an Adjuvant to Non-Small Cell Lung Carcinoma (NSCLC) Therapy.” Pilotti V, et al. Biotherapy. 1996.

“Adjuvant Treatment Using Transfer Factor for Bronchogenic Carcinoma: Long-Term Follow-Up.” Whyte Ri, et al. Ann Thorac Surg. 1992.

“Postoperative Immunostimulation After Complete Resection Improves Survival of Patients with Stage I Non-Small Cell Lung Carcinoma.” Fujisawa T, Yamaguchi Y. Cancer. 1996.

“Transfer Factor: Clinical Usage and Experimental Studies.” A Basten and S. Croft In: Immunological Engineering Jirsch DW (ed). MTP Press Ltd., Falcon House. 1978.

“Transfer Factor in Malignancy.” Pizza G, De Vinci C, Fudenberg HH. Progress in Drug Research, 1994.

Blind study conducted by Dr. Anatoli Vorobiev at the Russian Academy of Medical Science.

www.transferfactorinstitute.com
CONTACT US WATCH MOVIES DOWNLOAD CENTER